VANGUARD GROUP INC - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 147 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$18,548,009
-49.2%
1,660,520
-2.7%
0.00%
-100.0%
Q2 2023$36,512,145
-41.3%
1,706,175
+11.0%
0.00%
-50.0%
Q1 2023$62,152,357
-12.2%
1,536,903
+1.0%
0.00%0.0%
Q4 2022$70,812,232
-7.6%
1,522,189
+3.1%
0.00%0.0%
Q3 2022$76,609,000
+6.9%
1,476,910
-2.6%
0.00%0.0%
Q2 2022$71,694,000
-36.6%
1,516,689
-4.6%
0.00%
-33.3%
Q1 2022$113,122,000
-7.0%
1,589,224
-2.3%
0.00%0.0%
Q4 2021$121,586,000
+18.9%
1,625,909
-9.7%
0.00%0.0%
Q3 2021$102,278,000
+25.1%
1,800,363
-3.1%
0.00%
+50.0%
Q2 2021$81,727,000
-12.7%
1,857,019
-2.2%
0.00%
-33.3%
Q1 2021$93,642,000
+23.5%
1,898,674
+5.4%
0.00%
+50.0%
Q4 2020$75,804,000
-3.8%
1,800,579
+4.6%
0.00%
-33.3%
Q3 2020$78,782,000
-7.2%
1,720,890
+1.8%
0.00%0.0%
Q2 2020$84,895,000
-2.3%
1,690,797
+0.0%
0.00%
-25.0%
Q1 2020$86,930,000
-17.1%
1,690,260
-0.4%
0.00%0.0%
Q4 2019$104,885,000
+3.5%
1,697,729
+0.6%
0.00%0.0%
Q3 2019$101,345,000
-25.9%
1,686,848
+4.1%
0.00%
-20.0%
Q2 2019$136,751,000
-11.8%
1,620,650
-0.2%
0.01%
-16.7%
Q1 2019$155,056,000
+43.5%
1,623,291
+6.4%
0.01%
+20.0%
Q4 2018$108,075,000
-11.4%
1,525,834
+6.9%
0.01%0.0%
Q3 2018$121,934,000
-4.0%
1,426,791
+30.1%
0.01%0.0%
Q2 2018$127,075,000
+81.3%
1,096,417
+26.5%
0.01%
+66.7%
Q1 2018$70,100,000
+45.4%
866,391
+5.4%
0.00%
+50.0%
Q4 2017$48,216,000
+23.0%
821,687
-1.9%
0.00%0.0%
Q3 2017$39,198,000
+28.6%
837,563
-1.1%
0.00%0.0%
Q2 2017$30,475,000
+24.9%
847,021
+6.9%
0.00%
+100.0%
Q1 2017$24,399,000
-1.5%
792,165
+7.2%
0.00%0.0%
Q4 2016$24,761,000
+33.5%
739,158
+6.1%
0.00%0.0%
Q3 2016$18,543,000
+29.3%
696,877
+7.1%
0.00%0.0%
Q2 2016$14,345,000
-22.7%
650,560
+3.0%
0.00%0.0%
Q1 2016$18,547,000
-8.8%
631,489
+2.5%
0.00%0.0%
Q4 2015$20,340,000
-92.3%
616,028
-92.0%
0.00%
-90.0%
Q3 2015$265,068,000
+1813.7%
7,686,826
+2396.7%
0.01%
+900.0%
Q2 2015$13,851,000
+59.0%
307,882
+8.2%
0.00%0.0%
Q1 2015$8,711,000
-35.0%
284,476
+8.0%
0.00%0.0%
Q4 2014$13,396,000
+39.7%
263,446
+8.7%
0.00%0.0%
Q3 2014$9,587,000
+23.7%
242,260
+34.7%
0.00%0.0%
Q2 2014$7,749,000
+15.6%
179,910
+7.3%
0.00%0.0%
Q1 2014$6,703,000
+400.2%
167,631
+241.3%
0.00%
Q4 2013$1,340,000
+90.9%
49,119
+60.4%
0.00%
Q3 2013$702,000
+28.6%
30,630
-0.6%
0.00%
Q2 2013$546,00030,8260.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 511,186$43,686,00011.23%
GREAT POINT PARTNERS LLC 210,400$17,981,0002.80%
ARMISTICE CAPITAL, LLC 456,000$38,970,0002.34%
Matarin Capital Management, LLC 210,208$17,964,376,0001.16%
Sapphire Star Partners LP 8,168$698,0000.70%
Granahan Investment Management 103,320$8,830,0000.48%
FARALLON CAPITAL MANAGEMENT LLC 867,500$74,137,0000.44%
361 CAPITAL LLC 19,040$1,627,0000.35%
ALGERT GLOBAL LLC 17,922$1,532,0000.33%
Ativo Capital Management LLC 14,031$1,199,0000.32%
View complete list of ENANTA PHARMACEUTICALS INC shareholders